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Abstract 
Rhodiola rosea L. is a worldwide popular plant with adaptogenic activities that have been and currently 
are exploited in the traditional medicine of many cultures as well as examined in clinical trials. More than 
140 phytochemical structures have been identified, which belong to several natural product classes, 
including phenylpropanoid glycosides, phenylethanoids, flavonoids and essential oils and are mainly 
stored in the rhizomes and the roots of the plant. A number of mechanisms contribute to the adaptogenic 
activities of R. rosea preparations and its phytochemical components. Among them, the intrinsic 
inducible mammalian stress responses and their effector proteins, such as heat shock protein 70 (Hsp70), 
are most prominent. Due to its popular medicinal use, which has led to depletion of its natural habitats, R. 
rosea is now considered endangered in most parts of the world. Conservation, cultivation and 
micropropagation are all implemented as potential preservation strategies. A number of in vitro systems 
of R. rosea are being developed as sources of pharmaceutically valuable secondary metabolites. These are 
greatly facilitated by advances in elucidation of the biosynthetic pathways and the participating enzymes, 
which catalyse the production of these secondary metabolites in the plant. In addition, biotechnological 
approaches, such as calli and suspension cultures, show promise towards achieving sustainable production 
of R. rosea secondary metabolites. 
 Keywords: roseroot; medicinal use; clinical trials; in vitro cultures; secondary metabolites 
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Abbreviations 
2.4-D 2.4-Dichlorophenoxyacetic acid IAA Indole-3-acetic acid 
AEs  Adverse events IBA  Indole-3-butyric acid 
BAP 6-Benzylaminopurine Kin Kinetin 
BAX Bcl-2-associated X protein MeJa Methyl jasmonate 
Bcl-2 B-cell lymphoma-2 MS Murashige and Skoog 
CA Cinnamyl alcohol NAA Naphtaleneacetic acid 
cAMP  Cyclic adenosine monophosphate NMR Nuclear magnetic resonance 
DW Dry weight NQO1 
 
NAD(P)H:quinone oxidoreductase 1 
eNOS Endothelial nitric oxide synthase Phe L-Phenylalanine 
GA3 Gibberellic acid THMP Traditional herbal medicinal products 
GC-
MS 
Gas chromatography-mass 
spectroscopy 
Tyr L-Tyrosine 
GMP Good manufacturing practices TyrDC Tyrosine decarboxylase 
HIF1  Hypoxia-inducible factors 1 UDP 
 
UDP-glucose:tyrosol 
glucosyltransferase 
HPLC High performance liquid 
chromatography 
Zea  
 
Zeatin 
Hsp70  Heat shock protein 70   
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Introduction. 
Rhodiola rosea L. (roseroot or golden root) is a multipurpose medicinal plant with well 
established adaptogenic properties, able to increase the body’s nonspecific resistance and 
normalizing its functions in response to different stressors of emotional, mental, and physical 
origin (Olsson et al. 2009). R. rosea extracts, as well as its valuable pharmacologically active 
substances, such as salidroside, tyrosol, and rosavins, are extensively studied for their 
neuroprotective (Chen et al. 2008), hepatoprotective (Wu et al. 2009), antioxidant (Chen et al. 
2009), antiviral (Wang et al. 2009), anticancer (Hu et al. 2010) and anti-inflammatory activities 
(Guan et al. 2011a). Scientific research and clinical studies have confirmed the safety of R. rosea 
and its effectiveness as a psychostimulant, general strengthener, and antistress agent (Chiang et 
al. 2015). Understanding the signalling and regulatory system functioning on cellular level is 
important in elucidation the defence mechanism and the specific features of the adaptogenic 
activity (Volkova et al. 2013). 
The pronounced physiological and pharmacological activities of R. rosea lead to 
indiscriminate harvesting and depletion of its natural habitats (Bai et al. 2014). Therefore, it is a 
priority plant with vulnerable to critically endangered status, strictly forbidden for harvesting 
(Platikanov and Evstatieva 2008; Cuerrier et al. 2015) and included in the Red List of protected 
plant species in many countries throughout the world (Mossberg and Stenberg 2003; Sidjimova 
et al. 2014). 
Hence the application of plant in vitro cultures as a sustainable platform for 
biotechnologically production of pharmaceuticals is a promising alternative. In vitro cultures 
possess numerous advantages, including biosynthesis of biosafe metabolites according to the 
good manufacturing practices (GMP) and independency of the environmental factors. Also 
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opportunities for facilitating the down-stream processes resulting in increased yields of the target 
metabolites through different biotechnological approaches are available (Steingroewer et al. 
2013; Marchev et al. 2014; Grech-Baran et al. 2015). 
The aim of this review is to summarize the current status of R. rosea in terms of its biological 
activities, medicinal use with emphasis of the responsible molecular mediators and relevant 
application in clinical practice. Special attention of the in vitro cultures as a biotechnological tool 
for secondary metabolite biosynthesis is assigned. The proposed biosynthetic pathways of 
salidroside and cinnamyl alcohol glycosides, as well as, several considerations, including 
nutrient medium optimization, precursor feeding and genetic engineering with the aim of 
enhancing their yields are reviewed in details. The prospects of future scientific research are 
highlighted as well. 
Phytochemical composition of Rhodiola rosea 
The initial investigation of roseroot phytochemical profile began in the 1960s. To date, 
HPLC-, GC-MS- and NMR-based metabolomics have identified the structures of approximately 
140 compounds which belong to different natural product classes (Panossian et al. 2010; Joset et 
al. 2011). Most of its pharmaceutically active secondary metabolites (table 1) are mainly stored 
in the rhizomes and roots. A large collection of flavonoid compounds has been isolated from the 
rhizome (rhodionin, rhodiosin, rhodiolin, 8-methylherbacetin, acetylrhodalgin, kaempferol 7-O-
α-L-rhamnopyranoside and methyl gallate) and the areal parts of the plant (rhodionin, 
rhodionidin, rhodiolgin, rhodiolgidin, rhodalin, rhodalidin and caffeic acid) (Kurkin et al. 1985). 
Some of the main chemical compounds are structurally presented on figure 1. 
Roseroot also contains a relatively small amount of essential oils, mostly in its roots and 
rhizomes. According to different studies, the composition of the essential oil varies, but the most 
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frequently identified compounds are geraniol, n-decanol, myrtenol, trans-pinocarveol (Rohloff 
2002, Héthelyi et al. 2005, Shatar 2007, Evstatieva et al. 2010). 
Several types of glycosides have been found in R. rosea L. Salidroside, the most studied 
compound of roseroot was first isolated in 1967 by Troshchenko and Kutikova along with its 
aglycone, tyrosol and was named rhodioloside. Rhodioloside was later re-identified as 
salidroside (Thieme, 1969), which was first found in Salix triandra L., and even the name 
salidroside is derived from the Salix name (György 2006). Zapesochnaya and Kurkin (1982) 
isolated phenylpropanoid glycosides from R. rosea rhizome, identified as the glycosides of 
cinnamyl alcohol and named rosin, rosarin and rosavin, collectively called ‘‘rosavins’’. A 
phytochemical profile comparison of 21 Rhodiola species revealed the specificity of cinnamyl 
alcohol glycosides for R. rosea, which can distinguish it from all other Rhodiola species (Kurkin 
et al. 1986).  
Coumarins, lactones (Furmanowa et al. 1995) and phenolic acids: chlorogenic-, 
hydroxycinnamic- and gallic acid (Brown et al. 2002) were also found in R. rosea. Lotaustralin 
was isolated from the roots (Akgul et al. 2004). Today, rosin, rosavin, rosarin and salidroside are 
considered as diagnostic marker compounds of R. rosea, all demonstrating adaptogenic activity 
(Furmanowa et al. 1995; Germano et al. 1999; Panossian and Wagner 2005). 
A remarkable deviation in the active metabolite contents and constituents was observed in a 
study aiming to analyze the marker compounds in individuals of an Austrian R. rosea wild 
population (Mirmazloum et al. 2015a). The recently published results, along with the growing 
number of reports on the authenticity and quality control of R. rosea products (Xin, 2015; 
Booker et al. 2015) are increasingly justifying the importance of in vitro systems optimization 
for reliable and homogenous plant material production. 
8 
 
Medicinal use and ethnopharmacology of Rhodiola rosea: a focus on the molecular 
mediators  
R. rosea is widely recognized as an adaptogen, i.e. a substance, which elicits a state of 
increased overall resistance, thereby allowing the organism to counteract and adapt to conditions 
of extreme stress. Documents regarding the medicinal use and ethnopharmacology of R. rosea 
date back from the 1700s. The use of the root of this plant for the treatment of various 
conditions, including headaches, hernia, and diseases of the skin and kidney were reported in 
Linné’s Materia Medica, the first Swedish Pharmacopeia, and a book of useful plants from 
Iceland; this has been reviewed previously (Panossian et al. 2010). In the 19th century, R. rosea 
was used in France, Germany and many other European countries as a folk medicine to fight 
fatigue.  
More recently, R. rosea has emerged as one of the most popular plant adaptogens utilized in 
Europe, especially in Russia, where it had been recommended by the Pharmacological 
Committee of the Ministry of Health as a stimulant to improve stamina, memory, and mood 
(Saratikov and Krasnov, 2004). In Siberia, R. rosea is used to increase physical endurance, work 
productivity, longevity, treat fatigue and depression, and enhance resistance to high-altitude 
sickness (Panossian et al. 2010). Similarly, in the traditional medicine of China and Tibet, R. 
rosea is commonly used for the treatment of high-altitude sickness and hypoxia. Furthermore, 
various R. rosea preparations are used world-wide as dietary supplements and are claimed to 
“contribute to optimal mental and cognitive activity” (Khanum et al. 2005). 
These numerous health beneficial effects are supported by a gene expression profiling in a 
human neuroglia cell line (T98G) after exposure to a R. rosea extract (Panossian et al. 2014). 
The analysis of the data has revealed multiple transcriptional alterations, affecting the expression 
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of 1062 genes. The most significant changes in gene expression are associated with 
cardiovascular, metabolic, gastrointestinal, neurological, endocrine, behavioral, and 
psychological parameters. Pathway analysis showed changes affecting communication between 
innate and adaptive immune cells, eNOS signaling, altered T and B cell signaling in rheumatoid 
arthritis, axonal guidance signaling, G-protein coupled receptor signaling, glutamate receptor 
signaling, ephrin receptor signaling, cAMP-mediated signaling, and atherosclerosis signaling.  
The findings from the gene expression profiling are in close agreement with previous 
investigations demonstrating the antioxidant, anti-hypoxic, immunomodulatory, cardioprotective 
and neuroprotective activities of R. rosea preparations. Many of the experimental studies on the 
medicinal properties of R. rosea have been extensively reviewed (Grech-Baran et al. 2014; 
Chiang et al. 2015). It is becoming increasingly clear that several mechanisms contribute to the 
adaptogenic activities of R. rosea preparations and its phytochemical components (Panossian and 
Wikman, 2009; Panossian et al., 2010a). In this section, we focus on the reports that link the 
health beneficial effects of extracts of R. rosea and salidroside with specific molecular mediators 
and cellular processes that are common in the pathogenesis of chronic disease.  
Oxidative stress and the ensuing tissue damage are involved in the pathogenesis of 
essentially all chronic diseases, such as neurodegenerative, cardiovascular and immune system 
diseases. Preparations of R. rosea or salidroside protect against oxidative damage caused by 
hydrogen peroxide in numerous experimental systems involving different cell types, including 
human neuroblastoma cells (SH-SY5Y and IMR-32) (Zhang et al. 2007; Schriner et al. 2009), 
human osteosarcoma cells (Schriner et al. 2009), human fetal lung fibroblasts (Mao et al. 2010), 
human hepatocytes (Guan et al. 2011b), human cortical neurons (HCN 1-A) (Palumbo et al. 
2012), human endothelial and endothelial progenitor cells (Xu et al. 2013; Zhao et al. 2013; Tang 
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et al. 2014; Xing et al. 2014), rat pheochromocytoma cells (PC12) (Cai et al. 2008), primary 
cultured rat hippocampal and cortical neurons (Chen et al. 2009; Shi et al. 2012), and rat 
cardiomyoblasts (H9c2) (Zhu et al. 2011).  
In addition to its protective effects against oxidative stress, salidroside also protects against 
hypoxia-mediated damage in cultured cardiomyocytes and PC12 cells (Zhang et al. 2009; Zhong 
et al. 2014), and in vivo in mice (Huang et al. 2015). The latter study examined the effect of 
salidroside in a mouse model of pulmonary arterial hypertension induced by chronic hypoxia. 
Salidroside attenuated the right ventricular hypertrophy and pulmonary arterial remodelling. By 
examining the apoptosis factors, Bax, Bcl-2, cytochrome c, and caspase 9, it was found that 
salidroside reversed the hypoxia-mediated apoptosis resistance. In addition, salidroside treatment 
upregulated the expression of adenosine A2A receptor, a member of the G protein-coupled 
receptor (GPCR) family, which has a protective function against pulmonary arterial remodelling 
(Xu et al. 2011).  
The effects of salidroside on the family of transcription factors hypoxia-inducible factors 1 
(HIF1) have been also examined. The HIF1 family members are central regulators of oxygen 
homeostasis and mediators of cellular responses to hypoxia (Semenza, 2012; Kenneth and Rocha 
2008). One study found that salidroside treatment reduced the hypoxia-induced levels of HIF1 in 
SH-SY5Y cells (Li et al. 2010). In contrast, another study reported that in human embryonic 
kidney fibroblasts (HEK293T) and human hepatocellular carcinoma cells (HepG2) salidroside 
induced the accumulation HIF1 (by inhibiting its degradation) and the subsequent gene 
expression of erythropoietin from its transcription regulatory element, hypoxia response element 
(HRE) (Zheng et al. 2012). Accumulation of HIF1 was also observed in cultured human 
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umbilical vein endothelial cells after pre-treatment with salidroside, followed by exposure to 
hydrogen peroxide (Xu et al. 2013). 
Several molecular mechanisms contribute to the adaptogenic activity of R. rosea preparations 
(Panossian and Wikman 2009; Panossian et al. 2010). One of the key mediators is the inducible 
molecular chaperone, heat shock protein 70 (Hsp70) (Panossian et al. 2009; Hernández-Santana 
et al. 2014). Moreover, it has been proposed that Hsp70 can be used as a molecular biomarker for 
adaptogenic activity (Asea et al. 2013). Hsp70 inhibits the expression of inducible nitric oxide 
synthase (iNOS) (Hauser et al. 1996) and interferes with the function of the glucocorticoid 
receptor directly by participating in its unfolding (Kirschke et al. 2014). Hsp70 inhibits the 
stress-activated c-Jun N-terminal protein kinase 1 (JNK1), thereby regulating JNK-mediated cell 
signaling (Mosser et al. 1997; Yaglom et al. 1999; Simar et al. 2012; Kim et al. 2015) in a 
manner independent of its chaperone activity (Yaglom et al. 1999). Consequent to inhibition of 
the glucocorticoid receptor and iNOS expression, Hsp70 affects the levels of circulating cortisol 
and nitric oxide (NO). This in turn, prevents stress-induced ATP depletion, leading to increased 
mental and physical performance and endurance (Panossian and Wikman 2009).  
Hsp70 is transcriptionally inducible as part of two major cytoprotective mechanisms, termed 
the heat shock response and the phase 2 response, which can be triggered by various stimuli, 
including thermal, osmotic, oxidative and electrophilic stress, and allow cells and organisms to 
adapt and survive under unfavourable conditions (Talalay et al. 2000; Akerfelt et al. 2010; 
Morimoto et al. 2011; Dayalan Naidu et al. 2015). Induction of the heat shock response and the 
phase 2 response is controlled by two central regulators, heat shock factor 1 (HSF1) and nuclear 
factor-erythroid 2-related factor (NRF2), respectively. Emerging evidence suggests that, at least 
under certain conditions, R. rosea may cause activation of HSF1 and/or NRF2 in mammalian 
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cells. In human neuroglia cells, silencing of HSF1 leads to a significant suppression of the 
enhanced Hsp70 expression promoted by a standardized preparations containing R. rosea or 
salidroside (Panossian et al. 2012). One study has reported that the antioxidant activity of R. 
rosea is most likely independent of NRF2 activation: although there was a modest induction in 
reporter gene expression, there were no obvious changes in the levels of NRF2 target proteins 
(Schriner et al. 2009). However, it is noteworthy that salidroside was recently found to inhibit 
pulmonary fibrosis in rats treated with bleomycin, and that this inhibition was accompanied by 
stabilization of NRF2 and increased levels of its downstream target proteins NAD(P)H:quinone 
oxidoreductase 1 (NQO1), heme oxygenase 1 (HMOX1), and suppression of pro-inflammatory 
responses (Tang et al. 2015). In addition, salidroside protects H9c2 cardiomyocytes against 
ischemic damage caused by oxygen and glucose deprivation/re-oxygenation (Zheng et al. 2014). 
This protective effect is accompanied by an increase in NRF2 target gene expression, and is 
diminished by knockdown of NRF2. It is thus possible that the cytoprotective activity of R. rosea 
preparations under certain stress conditions is mediated, at least in part, through activation of 
HSF1 and/or NRF2.  
The ability to inhibit the activity of enzymes, which participate in the degradation of 
monoamines, and consequently to affect the levels of serotonin, dopamine and norepinephrine in 
the cerebral cortex, hypothalamus and the brain stem (Stancheva and Mosharrof 1987), to 
prevent catecholamine release and the subsequent increase in the levels of cAMP (Maslova et al. 
1994), and to activate opioid receptors (Lishmanov et al. 1997) have also been reported to 
provide functional means by which R. rosea extracts may exert their adaptogenic activity. 
In summary, the available experimental evidence showing that exposure to R. rosea extracts 
or salidroside causes multiple transcriptional and functional alterations in the mammalian cell 
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with clear benefits to the immune, cardiovascular, and nervous systems, provide scientific 
support for its continued medicinal use. 
Clinical trials 
 Herbal medicines have to demonstrate both safety and quality according to the Traditional 
Herbal Scheme required by the European Directive on Traditional Herbal Medicinal Products 
(THMP) (2004/24/EC). Vitango (based on R. rosea extract WS 1375), was registered as a 
traditional herbal medicinal product in 2009 (Hung et al. 2011). The preparations Rosenrot and 
Arctic Root (based on SHR-5 extract) are currently registered as THMP (Panossian et al. 2010). 
Extracts used in most clinical trials are standardized to minimum 3% cinnamyl alcohol 
glycosides (rosavins) and 0.8-1% salidroside as the naturally occurring ratio of these compounds 
in the plant rhizomes is approximately 3:1 (Brown et al., 2002). Over 46 companies worldwide 
sell R. rosea products and over 30 companies supply them as food ingredients. R. rosea is traded 
in preparations such as alcoholic extracts, tablets, capsules or in combination with other 
medicinal plants and/or honey (Platikanov and Evstatieva 2008). 
After numerous placebo-controlled randomized clinical trials, R. rosea proved to be safe in 
acute and subacute toxicity studies (Panossian and Wikman 2010; Hung et al. 2011). Adverse 
events (AEs) due to R. rosea intake are rare and mild (sleepiness and cold extremities) (Aslanyan 
et al. 2010; Hung et al. 2011). R. rosea has the potential to enhance the action of stimulating 
medications, therefore, should not be used concomitantly with such medications. The use of R. 
rosea is also not recommended during pregnancy or lactation (Ross 2014). Most of the clinical 
studies with R. rosea have been conducted in Russia and Sweden, where it has already been 
established as a psychostimulant, general strengthener, and antistress agent (Ross 2014). 
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Mental health conditions. Olsson et al. (2009) assessed the efficacy of the standardized 
extract SHR-5 of roots of R. rosea in the treatment of individuals suffering from stress-related 
fatigue. The participants (males and females), aged between 20 and 55 years, classified in two 
groups, experienced difficulties equivalent to the criteria of “fatigue syndrome”. After 28 days of 
treatment with SHR-5 extract (576 mg extract/day), a significant positive change was recorded in 
terms of Pines’ burnout scale (physical, emotional and mental exhaustion), mental health, 
attention and quality of life (Olsson et al. 2009). Reduction of fatigue and improvement in 
quality of life in a set of tests collectively calculated as a “Total Fatigue Index”, during 42 days 
of treatment of physicians on night shift (18-55 years of age) was reported. The daily dose of R. 
rosea extract (2.8% total rosavins) was 364 mg, but the authors noticed some AEs, based on 
which they recommended higher doses of the extract to confirm its effectiveness in further 
studies (Punja et al. 2014). Intake of SHR-5 standardized extract at 340 mg/day had lower 
antidepressant effect than sertraline. This extract showed significantly less AEs and was better 
tolerated in patients with mild to moderate depression (Mao et al. 2015). 
Mental performance. Acute R. rosea ingestion (3mg/kg) decreased the heart rate response to 
sub-maximal exercise, and improved endurance exercise performance, mood and cognitive 
function in 15 recreationally active college women (21±0.09 years) (Buckley and Lewis 2009). 
Aslanyan et al. (2010) evaluated the single dose effect of ADAPT-232 (fixed combination of 
dried extracts form roots of R. rosea, berries of Schizandra chinensis (Turcz.) Baill and roots 
Eleutherococcus senticosus Maxim on mental performance. Twenty out of forty healthy females 
(between 20 to 68 years of age) received a single tablet of ADAPT-232 (270 mg). In two hours 
the ADAPT-232 group gained improved attention and increased speed and accuracy during a 
cognitive test (evaluated by d2 Test of Attention). The subjects in this group had also lower 
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percentage of errors; improved accuracy, quality of work and degree of care in stressful 
conditions (Aslanyan et al. 2010). Daily doses of 300 mg extract (3% rosavins and 1% 
salidroside) for 28 days increased the general intelligence in healthy volunteers aged between 26 
and 56 years. It was concluded that the mechanisms of action include cholinesterase inhibition, 
anti-oxidant and anti-inflammatory activities, increased blood flow and energy metabolism 
(Stough et al. 2011). 
Physical performance. Dosing strategy of R. rosea phytopreparations for one month may 
attenuate muscle damage and inflammation. After consumption of 340 mg standardized R. rosea 
extract RHODAX (30 mg of ‘‘actives’’, i.e., rosavins plus salidroside) twice per day for 30 days 
by young untrained participants, decreased exercise-induced inflammation and muscle damage 
during a 6-day period of intense exercise was observed. The blood concentrations of C-reactive 
protein (CRP) and creatinine kinase (CK), serving as inflammation markers were significantly 
lower in the treated group in comparison with the control (Abidov et al. 2004). Contrary of the 
expectations, in experienced male and female runners, R. rosea extract (prepared by PoliNat SL, 
Las Palmas, Spain) did not attenuate the post-race muscle damage, soreness, and inflammation 
experienced by the runners, or the decrement in muscle function (Shanely et al. 2014). Treatment 
with salidroside (600 mg/day) exhibited a protective effect on epirubicin-induced early left 
ventricular regional systolic dysfunction in patients with histologically confirmed breast cancer. 
At a higher cumulative dose of epirubicin (300 mg/m2), the strain rate was normalized only with 
the intake of salidroside (Zhang et al. 2012). 
Preservation strategies of R. rosea. 
Rhodiola rosea L. (synonyms: Sedum rosea (L.) Scop., belongs to the Crassulaceae family, 
Sedoideae subfamily, Sedeae tribe, Umbilicinae subtribe (Engler 1964). Some species of the 
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genus were previously classified to the genus Sedum L., from which they were separated later 
(Index Kewensis 1895 - 1974). The genus Rhodiola consists of 136 accepted species (Grech-
Baran et al. 2015), occurring mainly in Asia and Europe (Brown et al. 2002), and the most 
widespread species in Europe is R. rosea.   
R. rosea L. is a dioecious, perennial plant native to East Asia, Russia, Japan, Korea and 
Southern China (Martin et al. 2010). In the mountains it grows at altitudes between 2 000 and 2 
600 m (Platikanov and Evstatieva 2008) and very harsh conditions (intensive UV radiation, low 
oxygen concentration, alpine climate with low temperatures and growth on poor soils – mountain 
limestone, granite and sandstone regions or rock crevices) (Ling-ling et al 2007).  The natural 
area of distribution of R. rosea is wide and includes most of the boreal and temperate parts of the 
Northern hemisphere. In Europe the species occurs in the cool temperature regions of the 
Northern, central and South-eastern parts of the continent (Tutin 1964). Eastward it spreads to 
central and northern Asia (the subarctic and Siberia, Altai and the mountains of Mongolia) (Flora 
of China, 2010), and in North America – in the mountains of Alaska, Canada, and the continental 
United States (Small and Catling 1999). 
The natural habitats of R. rosea are at the edge of exhaustion due to indiscriminate harvesting 
of R. rosea plants for their valuable pharmacological substances (Ling-ling et al 2007; Bai et al. 
2014). That is why this species is with high conservation value throughout its area of 
distribution. It is one of the priority species for conservation in many European countries: 
Finland, Lithuania, Sweden, Norway and Iceland (Cuerrier et al. 2015). R. rosea is protected 
species with endangered status in Great Britain, Czech Republic, Bosnia and Herzegovina 
(Platikanov and Evstatieva 2008); critically endangered in Bulgaria (Sidjimova et al. 2014) and 
vulnerable in Slovakia (Galambosi et al. 2006), where its collection is strictly forbidden 
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(Platikanov and Evstatieva 2008). It is also a subject of protection in many former Soviet Union 
republics, as well as the Komi Republic (Taskaev 1999), the Central Urals, Arkhangelsk, Nenetz 
and Khanty Mansiysk Autonomous Area of the Russian Federation, including the Republic of 
Karelia (Kotiranta et al. 1998). R. rosea is also included in the Red Data Book of several 
countries, including Bulgaria (Sidjimova et al. 2014), Ukraine (Didukh 2009), Västra Götaland 
County (Scandinavia) and Göteborg and Bohuslän counties in Sweden (Mossberg and Stenberg 
2003). 
There are several strategies developed for the preservation of R. rosea, including field 
cultivation and micropropagation with the aim of restoring R. rosea to its natural habitats 
(Tasheva and Kosturkova 2010). 
Field cultivation. The first publications on the cultivation of R. rosea date back to 1970s when a 
collection was established in the experimental station of Upper Altai Pedagogical Institute 
(Dneprovskii et al. 1975). Cultivation started with transferring whole plants, which were used 
subsequently for seed production. Extensive collections were established during the last few 
decades in different parts of the former Soviet Union in Tomsk; Siberia; Petersburg; Syktyvkar. 
Successful cultivation of the species was reported in Russia; Scandinavia (Sweden, Finland and 
Norway); Alpine Countries (Austria, Italy, Germany and Switzerland); Carpathian Countries 
(Poland, Romania, Bulgaria, Moldova, Czech Republic and Slovak Republic); as well as other 
countries: Estonia, Great Britain and Mongolia (Galambosi 2015). 
Kudriavtseva and Viracheva (2006) reported long term results (1938 – 2006) of cultivation of 
15 Rhodiola species in the Kola Peninsula, northern Russia. The results showed that R. rosea is a 
long living plant, with a life span from 40 to 70 years and tolerant to the unfavourable ecological 
conditions (Kudriavtseva and Viracheva 2006). A technology for cultivation of R. rosea in 
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Bulgaria was published by Platikanov and Evstatieva (2008). They considered the ecological 
conditions in Bulgaria as unfavourable for seed propagation, mostly due to higher temperatures 
and lower air and soil humidity in comparison to other parts of its areal. Therefore, they 
recommended vegetative propagation by direct rooting of cuttings of 2-5 cm length (Platikanov 
and Evstatieva 2008). Mineral fertilization with N, P and K increased the raw material yield by 
about 30–40% and that of phenylpropanoids after 2 years of cultivation (Buchwald et al. 2015). 
Notably, most of the products on the market are based on raw material collected from wild 
populations from the Altai region. There are several organizations of different sizes in various 
parts of the world, including Alaska (http://www.alaskarhodiolaproducts.com), Alberta (Alberta 
Rhodiola Rosea Growers Organization), and Finland 
(http://personal.inet.fi/koti/sini.marjanen/rreng.htm), whose members are cultivating roseroot. 
Main disadvantage of the field cultivated R. rosea plants is that the accumulation of the 
secondary metabolites occurs after 5 to 7 years of cultivation (Grech-Baran et al. 2015) and the 
adaptation of the plants is difficult due to the specific climate conditions (Platikanov and 
Evstatieva 2008). 
Micropropagation. Protocols for in vitro plant organogenesis, regeneration and propagation 
using plants growing in nature were established. The key points in this approach are the 
establishment of suitable media for induction, multiplication and rooting of the shoots, their 
adaptation in to greenhouses and acclimatization in the natural habitats (Tasheva and Kosturkova 
2010; Tasheva and Kosturkova 2012a; Ghiorghită et al. 2011). The suitable concentration and 
combination of the plant growth regulators depends on the genotype, the ecotype, the explant 
type and its stage of development. Even a soft computing model for prediction of the optimal 
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nutrient media that give the best results for growing and rooting of R. rosea in vitro cultures was 
developed by Simeonova et al. (2013). 
For the micropropagation of R. rosea, Ghiorghită et al. (2011) concluded that the most 
suitable explants were shoot apices and nodes cultivated on hormone-free MS medium. Another 
efficient hormonal variant for micropropagation is also MS medium supplemented with NAA 
and Kin or IAA and Zea characterized with very intense rhizogenesis (Ghiorghită et al. 2011). 
The most appropriate media for shoot induction and multiplication was MS medium containing 
Zea and IAA, while rhizogenesis and root induction was achieved on MS medium supplemented 
with IAA, IBA and GA3, suggesting that IAA and IBA in combination have synergistic effect 
(Tasheva and Kosturkova 2010). Further acclimatization of the plantlets into a greenhouse (22-
24 °C, PFD of 40 µM m-2 s-1 (16/8 d/n) and 90% relative humidity and a 1:1:2 mixture of 
perlite:peat:soil) (Tasheva and Kosturkova 2010) or into septic environment in a hydroponic 
system was performed (Ghiorghită et al. 2011). Both approaches ensured high survival of the 
plantlets: 85 and 90%, respectively (Tasheva and Kosturkova 2010; Ghiorghită et al. 2011). 
When R. rosea plants were transferred in Rhodope Mountains (area Beglika, Bulgaria 1525 
meters altitude) 70% of the plants survived (Tasheva and Kosturkova 2010), which is a great 
success in comparison with other reports, where during the first year 73.5% of the plants 
survived and their number dropped to 57% in the second year when transferred in Ceahlău 
Mountains, Romania (1750 meters altitude) (Ghiorghită et al. 2011). The micropropagated plants 
in Rhodope Mountains contained higher levels of salidroside (0.61-0.64%) in comparison with 
the wild plant (0.36-0.44%), while those in Ceahlău Mountains had different leaf colour (light 
green) in comparison with green-gray colour of the native individuals (Tasheva and Kosturkova 
2010; Ghiorghită et al. 2011). 
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Rhodiola rosea in vitro systems as a source of pharmaceutically valuable secondary 
metabolites. Biosynthetic pathway of salidroside and cinnamyl alcohol glycosides 
Plant in vitro cultures have been endorsed as sustainable perspective for production of high-
value phytochemicals. These compounds are being produced under ecofriendly controlled 
process parameters according to the good manufacturing practices (GMP), thus ultimately 
providing continuous production of biosafe, bioactive and stable natural products. This approach 
eliminates the influence of environmental and seasonal factors and do not threaten the natural 
populations of rare and protected plant species.  Moreover, several strategies for enhancement of 
the desired metabolites could be applied, facilitating down-stream processes and resulting in 
increased yields of the target metabolites (Steingroewer et al. 2013; Marchev et al. 2014; Grech-
Baran et al. 2015). At the moment there is limited number of reports concerning secondary 
metabolite production from calli and suspension cultures of R. rosea. Scientific publications for 
induction and cultivation of hairy roots of this species are still lacking. The secondary 
metabolites biosynthesized by callus and suspension cultures of R. rosea (table 2) include 
phenylpropanoids: rosarin, rosavin, rosin, triandrin,  (Furmanowa et al. 1998; György et al. 2004; 
György et al. 2005; Krajewska-Patan et al. 2007a); phenylethanoids: salidroside, tyrosol 
(Krajewska-Patan et al. 2007a); phenolic acids: gallic, chlorogenic and caffeic, p-coumaric acid 
acid (Kurkin et al. 1991; Furmanowa et al. 1998; Krajewska-Patan et al. 2007a); 
proanthocyanidins: catechin, epicatechin, epigallocatechin, gallate epicatechin, gallate 
epigallocatechin (Gryszczyńska et al. 2012). 
R. rosea is growing very slowly (Ling-ling et al 2007; Mirmazloum et al. 2014). The 
cultivation of this species aiming high levels of biologically active substances is quite long and 
takes between 5 to 7 years (Furmanowa et al. 1999; Galambosi 2006) and very often the 
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biosynthesis of salidroside is in the low range, between 0.13-1.6 % DW (Furmanowa et al. 1999; 
Linh et al., 2000; Platikanov and Evstatieva 2008), and that of rosavins is between 0.1-3.0% DW 
(Furmanowa et al. 1999; Saunders et al. 2013), frequently with high deviation in the content 
between different species or even intraspecially due to heterozygosis, morphological and 
chemical variability (Weglarz et al. 2008; Mirmazloum and György 2012). Along with that, 
these substances are found in lower amounts in the field-cultivated R. rosea than the naturally 
growing plants (Ma et al. 2008). To meet the demands for roseroot metabolites, there have been 
many attempts for chemosynthesis of salidroside and rosavins, but all were ineffective due to 
high production costs (Ma et al. 2007). 
These challenges could be overcome by developing biotechnological methods to improve 
the production of R. rosea secondary metabolites through in vitro culture systems (Lan et al. 
2013; Mirmazloum et al. 2014). However, the in vitro produced metabolites are in lower 
amounts (György et al. 2004; György and Hohtola 2009), and in some cases have even failed to 
be produced by in vitro cultures (Martin et al. 2010) or needed specific requirements for their 
biosynthesis, such as addition of precursors (Grech-Baran et al. 2013). There are also reports for 
the successful biosynthesis of salidroside in microorganisms (Bai et al. 2014). One of the 
highlighted reasons for the low salidroside biosynthesis for example, is the low efficiency of 
glycosylation and the non-synchronization of UDP-glycosyltransferase activity with tyrosol 
accumulation (Xu et al. 1998a; Grech-Baran et al. 2013). For that reason there is considerable 
interest in the regulation of R. rosea secondary metabolites by modulating the expression of the 
endogenous enzymes at the rate limiting steps of the biosynthetic pathway (by overexpressing 
the pathway genes or/and by eliminating competing pathways and feedback inhibition) or by 
introduction of new enzymes (Ma et al. 2007; Ma et al. 2008; Bai et al. 2014). The metabolic 
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engineering is possible but dependent on the discovery of the genes expressing the relevant 
enzymes (Lan et al. 2013).  
Proposed biosynthetic pathway of salidroside 
Salidroside is a tyrosol 8-O-β-D-glucoside (Ma et al. 2008; Zhang et al. 2011) and mostly 
accumulates in rhizomes and roots of R. rosea (György et al. 2009). It is formed as a product of 
dehydration between the hemiacetal hydroxyl of glucose and the ethanol hydroxyl of tyrosol (4-
hydroxyphenylethanol) (Ling-ling et al. 2007).  The biosynthetic pathway of salidroside (figure 
2, arrow types B-G) is still elusive and its regulation is not very well understood (Ma et al. 2008; 
Bai et al. 2014). 
Salidroside and CAGs (rosin, rosavin and rosarin) have common precursors at the 
beginning of their biosynthetic pathway, including the L-amino acids phenylalanine (Phe) and 
tyrosine (Tyr) derived via the shikimate pathway, which is the main biosynthetic pathway of 
phenolics in higher plants (Ma et al. 2008; Mirmazloum and György 2012). 
The biosynthesis of salidroside can be divided into two stages: the biosynthesis of 
tyrosol, and the subsequent transfer of glucose to tyrosol in order to form salidroside (Ling-ling 
et al. 2007). In the available literatures there are two different opinions concerning the 
biosynthesis of tyrosol: one is that tyrosol is presumably produced by a decarboxylase from a p-
coumaric acid precursor, mainly deriving from Phe; and the second one is that the precursor of 
tyrosol is tyramine, which is synthetized from Tyr by tyrosine decarboxylase (Ma et al. 2008; 
Zhang et al. 2011). 
According to the first view, the biosynthesis of tyrosol starts with deamination of Phe to 
trans-cinnamic acid (Ling-ling et al. 2007; Ma et al. 2008), a reaction catalyzed by phenylalanine 
ammonia-lyase (PAL; EC: 4.3.1.5) (Ling-ling et al. 2007; Mirmazloum and György 2012). Phe 
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and Tyr can inhibit their own synthesis through feedback inhibition of chorismate mutase (Ma et 
al. 2008). This reaction is an offshoot in primary and secondary metabolisms in plants, and PAL 
has key regulatory functions. Trans-cinnamic acid is hydroxylated at position 4 of the aromatic 
ring to form para-coumaric acid by trans-cinnamate 4-monoxydase (C4H; EC: 1.14.13.11). 
Para-coumaric acid can be synthetized from Tyr as well by tyrosine ammonia-lyase (TAL; EC: 
4.3.1.23), phenylalanine/tyrosine ammonia-lyase (PTAL; EC: 4.3.1.25) and also by PAL enzyme 
with TAL activity (Mirmazloum and György 2012) (figure 2, D type arrows). Two possibilities 
have been described for the transformation of para-coumaric acid to tyrosol. The first one (figure 
2, C type arrows) is that para-coumaric acid is directly converted to tyrosol via decarboxylation 
by para-coumaric acid decarboxylase (pCD; EC: 4.1.1.-) (Ling-ling et al. 2007; Mirmazloum 
and György 2012). Nevertheless, there is still no confirmation available for the presence of pCD 
in plant species (Ma et al. 2008; Mirmazloum and György 2012). The second possibility (figure 
2, F and G type arrows) for tyrosol biosynthesis includes the conversion of para-coumaric acid 
into para-coumarol-CoA by 4-coumarate-CoA ligase (4CL; EC: 6.2.1.12), para-coumaraldehyde 
by cinnamoyl-CoA reductase (CCR; EC: 1.2.1.44), and finally para-coumaryl alcohol by 
cinnamyl alcohol dehydrogenase (CAD; EC: 1.1.1.195). It has been proposed that para-
coumaryl alcohol is further converted into tyrosol by still uncharacterized enzymes at least in 
two steps (indicated with question mark “?”) (Ling-ling et al. 2007).  
An important advance in clarifying the tyrosol biosynthesis was the overexpression of the 
endogenous PALrs1 gene in R. sachalinensis (Ma et al. 2008). As a result, there was a sharp 
decrease in tyrosine, tyrosol and salidroside content in comparison with the non-transgenic 
plants. The amount of para-coumaric acid increased by 3.3-fold, but it did not facilitate tyrosol 
biosynthesis. This is a clear evidence that tyrosol is not derived from Phe and that the observed 
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reduction of salidroside biosynthesis correlates with the availability of Tyr (Ma et al. 2008). This 
conclusion is further supported by the lack of correlation between PALrs1 transcriptional 
expression and the accumulation of salidroside. PALrs1 transcription, which was higher in calli 
than in stems and leaves and very low in roots, whereas the salidroside content was more 
pronounced in roots and calli and less in stems and leaves (Ma et al. 2008). 
The second view for tyrosol biosynthesis is that it derives from Tyr (figure 2, B and E 
type arrows) (Ma et al. 2008; György et al. 2009; Zhang et al. 2011; Lan et al. 2013). Tyr is 
converted to tyramine by tyrosine decarboxylase (TyrDC; EC: 4.1.1.25) (figure 2, B type 
arrows). TyrDC has a decisive role and crucial function not only in the initial conversion of 
tyrosol, but also a key regulatory function in the salidroside biosynthesis pathway as a whole 
(Ma et al. 2008; György et al. 2009; Zhang et al. 2011; Lan et al. 2013). TyrDC has a genotype 
and tissue dependent expression. Its expression is significantly higher in the roots than in leaves, 
stems or flowers in R. rosea and R. crenulata, which is in accordance with the high salidroside 
content it the roots (György et al. 2009; Lan et al. 2013). The salidroside content is significantly 
higher in transgenic hairy roots of the same species (Lan et al. 2013), as well as in R. 
sachalinensis (Zhang et al. 2011), containing TyrDC gene. This information supports the opinion 
that salidroside biosynthesis begins with the decarboxylation of Tyr by TyrDC, which produces 
tyramine. More supporting facts show that the addition of 1 mM Tyr or 1 mM tyrosol increased 
9-fold the salidroside content in cell cultures of R. sachalinensis, resulting in the highest ever 
reported salidroside content by Rhodiola cell suspension culture (154.95 mg/g), while the Phe 
did not exhibit the same effect (Xu et al. 1998b). 
The next step in the tyrosol synthesis is the conversion of tyramine to 4-
hydroxyphenylacetaldehyde (4-HPAA) by primary-amine oxidase (CAO; EC: 1.4.3.21) 
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(Mirmazloum and György 2012). Another route for the biosynthesis of tyrosol is catalyzed by 
histidinol-phosphate transaminase (HPA; EC: 2.6.1.9) and aromatic-amino acid transaminase 
(AAT; EC: 2.6.1.57), which convert Tyr to 4-hydroxyphenylpyruvate (4-HPP) (figure 2, E type 
arrows). However, so far these enzymes have been reported only in Nicotiana tabacum L. and 
Vigna radiate (L.) R. Wilczek respectively. Afterwards, 4-HPP is converted to 4-HPAA by 4-
hydroxyphenylpyruvate decarboxylase (HPPD: EC: 4.1.1.80) (Mirmazloum and György 2012). 
Aryl-alcohol dehydrogenase (AAD; EC: 1.1.190) is responsible for the formation of tyrosol from 
4-HPAA, which has been recognized as the direct precursor of tyrosol, and the enzyme has been 
found in plants (Zhang et al. 2011). Recently, salidroside was synthetized in recombinant 
Escherichia coli from glucose through 4-HPP (key intermediate in the yeast Ehrlich pathway, 
derived from L-tyrosine by transamination). The key enzymes were the Saccharomyces 
cerevisiae pyruvate decarboxylase ARA10, which converted 4-HPP to 4-HPAA and the 
introduced plant-derived glycosyltransferase UGT73B6. A significant increase of salidroside 
biosynthesis was observed not only when the genes responsible for its biosynthesis were 
expressed, but when the competitive pathways and negative regulation were eliminated as well 
(Bai et al. 2014).  
Natural products, such as phenylpropanoids exist as glycosides in plants. The final step in 
salidroside (the storage form of tyrosol) biosynthesis is the transfer of a glucose molecule to 
tyrosol, which is catalyzed by UDP-glycosyltransferase by means of deploying UDP-glucose as 
the glucose donor (Ling-ling et al. 2007). Glycosylation can alter the solubility and transport of 
the compounds within the cell, stabilizing the product, and modulate its bioactivity and storage 
(Mirmazloum and György 2012). 
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UDP-glycosyltransferase is also very important key regulatory enzyme in salidroside 
biosynthesis along with TyrDC enzyme (Ling-ling et al. 2007; Yu et al. 2011; Lan et al. 2013). 
UDP-glycosyltransferase activity is in correlation with the tyrosol availability and can be 
significantly upregulated by tyrosol addition as a precursor in the media (Grech-Baran et al. 
2013) or treatment with MeJa (Lan et al. 2013). The expression of RcUDPGT was coordinated 
with the RcTYDC gene expression in R. crenulata (Lan et al. 2013) and the synchronized activity 
between TyrDC and UDP-glycosyltransferase in the hairy roots of R. kirilowii resulted in more 
pronounced synthesis of tyrosol and salidroside (Baran et al. 2013). However, in natural roots of 
R. kirilowii, tyrosol accumulation was not synchronized with the tyrosol glucosyltransferase 
activity (TGase) (Baran et al. 2013), which indicates that there might be other UGTs that are 
active toward tyrosol (Ma et al. 2007). UDP-glycosyltransferase is also a tissue specific enzyme 
and is more abundant in the roots of Rhodiola species and their in vitro cultures (Ma et al. 2007). 
The overexpression of UGT73B6 and UGT72B14 gene in R. sachalinensis was responsible for 
higher levels of salidroside (Ma et al. 2007; Yu et al. 2011), but compared to the UGT73B6 
transgenic plants and calli (Ma et al. 2007), the hairy roots exhibited higher level of salidroside 
(Yu et al. 2011).  
The accumulation of salidroside depends on the balance between its synthesis and 
degradation. The possible enzyme catalyzing its degradation is β-D-glucosidase (β-D-glucoside 
glucohydrolase; EC: 3.2.1.21), which is able to hydrolyze a range of glycosides. The enzyme has 
dual function: it can act as a hydrolase (hydrolyzes glycosides, releasing the glycosyl) or as a 
glucosyltransferase (transfers the glycosyl to other molecules, called aglycons). Till now it is still 
not clear if the dominant role of this enzyme is in the anabolism or catabolism of salidroside. It 
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still needs to be clarified by observing its activity during different developmental stages of the 
plant and in different plant tissues (Ling-ling et al. 2007). 
Proposed biosynthetic pathway of cinnamyl alcohol glycosides (CAGs) 
The production of rosin and its derivatives in the genus Rhodiola is restricted to only a 
few species. Biosynthesis of phenolic glycosides occurs spontaneously in R. rosea roots and 
rhizomes (Grech-Baran et al. 2015). In the proposed biosynthetic pathway of CAGs (figure 2, A 
type arrows), trans-cinnamic acid is converted to cinnamoyl-CoA by 4-coumarate-CoA ligase 
(4CL; EC: 6.2.1.12) via a two-step reaction mechanism that involves the hydrolysis of ATP 
(György 2006). Further, the reduction of cinnamoyl-CoA to cinnamaldehyde formation is 
catalyzed by the enzyme cinnamoyl-CoA oxidoreductase (CCR; EC: 1.2.1.44). Afterwards 
cinnamyl alcohol dehydrogenase (CAD; EC: 1.1.1.195) reduces the cinnamaldehyde to cinnamyl 
alcohol. This enzyme has different isoforms, some of which have a preference towards one of the 
available substrates. The combination of isoforms varies depending on the developmental stage 
and the tissue. The enzyme(s) that take(s) part in the formation of the glycosides of cinnamyl 
alcohol are not yet described. Rosin is the simplest glycoside of roseroot which is formed when 
one molecule of glucose attaches to cinnamyl alcohol. From rosin by the connection of an 
arabinose molecule, rosavin, and by the connection of an arabinofuranose molecule, rosarin is 
formed. Depending on the sugar type and the site it is attached to, further glycosides may be 
formed (Mirmazloum and György 2012). A very important precursor and inducer of the enzyme 
system responsible for the biosynthesis of CAGs is cinnamyl alcohol (CA). CAGs were not 
synthetized by non-transformed wild type (NTWT) and hairy roots from R. kirilowii unless CA 
was added to the media as a precursor at concentration of 2.5 mM in the presence of 1% sucrose 
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(Grech-Baran et al. 2014). It was established that cinnamoyl-CoA reductase (CCR) has greater 
impact on CAGs biosynthesis, than other enzymes, such as PAL (Mirmazloum et al. 2015b). 
In conclusions, the identification and regulation of the key enzymes is an important step in 
facilitating the metabolic flux flowing toward the downstream pathway leading to increased 
production of the end-products salidroside and CAGs, through overexpression of these enzymes 
at the rate-limiting points or by blocking enzymes at the branching points that can divert the 
metabolic flux to other secondary metabolites. 
Biotechnological tools for secondary metabolites enhancement 
The number of publications concerning in vitro cultures induction from R. rosea is still 
limited (Tasheva and Kosturkova 2014). In vitro cultures from R. rosea are extensively used for 
biotransformation procedures in order to enhance the secondary metabolite production or for 
micropropagation of plants for the restoration of exhausted habitats (Tasheva and Kosturkova 
2010). There are many factors affecting the in vitro culture induction from R. rosea, including 
plant ecotype, type of explants, nutrient medium compositions (plant growth regulators, carbon 
source and inorganic salts), light, temperature, and presence of precursors and elicitors,  
(Tasheva and Kosturkova 2010; Grech-Baran et al. 2015). The available literature reveals that 
obtaining in vitro cultures from this plant is not an easy task and faces many difficulties starting 
from the sensitivity of the explants to disinfection agents to obtaining viable calli lines and 
producing the desired compounds (Ghiorghită et al. 2011). The problem with the disinfection 
could be solved by short and soft sterilization procedure (3 to 6 min treatment with chloramine-
T, 5%) or by using in vitro explants obtained from sterile seedlings (Ghiorghită et al. 2011; 
Tasheva and Kosturkova 2010). The explant type can influence not only the callus morphology, 
but also its ability to produce secondary metabolites. Axially bud originated callus line produced 
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approximately 2-fold more rosavin than the hypocotyle originated callus line, the main feature of 
which was the high level of rosin: 1.2-fold higher than the axially bud callus (Krajewska-Patan et 
al. 2007a). BAP seems to favor the fast growth of the callus tissue. Apical buds and internode 
fragments, leaves and leaf disks inoculated on media containing BAP (0.2-1.5 mg/L) and IAA 
(0.1 mg/L) (Tasheva and Kosturkova 2010), NAA (0.5 mg/L) (György and Hohtola 2009), or 
2.4-D (0.5-1.0 mg/L) (Ghiorghită et al. 2011) were the most appropriate explants type and media 
compositions for induction of intensively growing green compact calli. But when 2.4-D was 
applied at higher concentrations (2 mg/L) spontaneous intense rhizogenesis and sporadic shoots 
formation was observed (Ghiorghită et al. 2011). 
Optimization of the nutrient medium by reduction of the concentration of sucrose from 30 
to 20 g/L increased the callus growth 2-3 fold, but no salidroside was synthetized (Tasheva and 
Kosturkova 2014). Rosavin was also not produced when sucrose was the single carbon source, 
but when 10 g of sucrose were replaced with glucose, the CAGs content increased 2-fold (Gyögy 
et al. 2005). In contrast, glucose addition simultaneously with tyrosol had no positive effect on 
salidroside production, compared to the single tyrosol feeding (Gyögy et al. 2005). Positive 
effect of antibiotics (cefotaxime and carbenicillin) has been reported to increase the in vitro 
biomass growth of R. rosea calli (Mirmazloum et al. 2015c). 
Regardless of the specific phytohormone combination or optimization of the nutrient 
composition, many reports confirm that secondary metabolites in R. rosea callus cultures are 
very often either not synthetized or synthesized in lower amounts compared to the intact plant 
(Furmanowa et al. 1998; Furmanowa et al. 1999; György et al. 2004; Martin et al. 2010). Many 
authors overcome this problem by applying different biotechnological approaches, including 
precursor feeding and genetic manipulation of R. rosea in vitro cultures. Since secondary 
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metabolites are considered as products linked with differentiation, in the case of R. rosea most 
authors prefer to work with compact callus aggregates (CCA) instead of homogenous cell 
suspension. Compact callus aggregates are spherical, smooth surfaced clumps displaying some 
level of cellular differentiation and no dispersed cells are observed when transferred in liquid 
media (György et al. 2004). Along with the type of precursor, the optimum amount and time of 
addition are also of importance. CA is one of the most effective precursors that increase or 
induce the biosynthesis of CAGs. When added at concentrations of 2 or 2.5 mM at the beginning 
of the cultivation of CCAs, the rosin content was induced and reached 0.72% DW (György et al. 
2004) and the content of rosavin reached 1.01% (Furmanowa et al. 1999). In the control samples, 
none of these metabolites were produced (Furmanowa et al. 1999; György et al. 2004). After 
feeding R. rosea callus culture with CA, several new glycosides as products of biotransformation 
were identified (György et al. 2004; Tolonen et al. 2004). With addition of 2.5 mM CA, a 
remarkable increase in the content of rosin in the hypocotyle originated callus was observed, 
while the axially bud originated callus line produced 1.2-fold less rosin and 2-fold more rosavin 
compared to the first line. The content of salidrosede in hypocotyle originated callus increased to 
concentration similar to the intact plant, while the amount of tyrosol and chlorogenic acid were 
20-fold higher (Krajewska-Patan et al. 2007a). The content of salidroside can be enhanced by 
exogenous addition of p-tyrosol as a precursor. Its addition (5 mM) in solid and liquid CAA 
culture increased the level of salidroside reaching up to 4.3% DW (Krajewska-Patan et al. 
2007b) 
A promising and effective approach to enhance the secondary metabolite production by R. 
rosea in vitro cultures is the application of genetic engineering for regulation of their 
biosynthetic pathways through the enzyme activities involved. The most widely employed 
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method includes a transformation step, mediated by Agrobacterium tumefaciens with the aim to 
introduce DNA encoding definite enzyme activity into the plant genome. This approach 
concerning in vitro cultures of R. rosea is still at its beginning. Mirmazloum et al. (2014) 
developed a consistent method for genetic transformation of R. rosea cell cultures, which can be 
used as a tool to enhance the pharmaceutically important metabolites through expression or 
suppression of the involved key genes in the plant genome (Mirmazloum et al. 2014). Several 
investigations performed with in vitro cultures of R. sachalinensis and R. crenulata confirmed 
that overexpression of genes encoding key enzymes, such as PAL, TyrDC and UDP-
glycosyltransferase can successfully direct the biosynthetic pathway towards the target 
metabolites: salidroside and CAGs, and increase their concentrations (Ma et al. 2007; Yu et al. 
2011; Zhang et al. 2011; Lan et al. 2013). However, similar investigations based on R. rosea in 
vitro cultures are still missing in the available literature. Based on the analysis of the plant R. 
rosea, György et al. (2009) proved that TyrDC has an organ-specific expression. The expression 
of the gene encoding this enzyme was significantly higher in the roots, which corresponds with 
the fact that salidroside, accumulates preferentially in the underground parts of the plant. The 
expression n in the leaves was lower than in the roots (György et al. 2009). 
The choice of in vitro culture as a biotechnological tool for secondary metabolite production 
depends also on the localization of the target secondary metabolites in the intact plant (Martin et 
al. 2010). Since salidroside and CAGs are dominantly accumulated in the roots of the plant, 
therefore hairy roots should be a reliable alternative for their biosynthesis. Hairy roots are 
genetically and metabolically stable and are able to produce secondary metabolites similar to the 
intact plants: hence they can be used as a sustainable platform for in vitro biosynthesis of 
secondary metabolites (Marchev et al. 2014; Georgiev 2014). The single report in the available 
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literature for hairy root induction belongs to R. rosea is from Tasheva and Kosturkova (2012b). 
In spite of detailed investigations by using three different approaches for genetic transformation 
of R. rosea with A. rhizogenes ATCC 15834 and optimization of bacterial suspension density, 
co-cultivation time and antibiotic concentration, the authors obtained frustrating results. Their 
explanation for the negative response to hairy root induction was the high concentration of 
reactive oxygen species produced by R. rosea explants, which destroyed the bacteria and caused 
necrosis of the explants (Tasheva and Kosturkova 2012b). The same obstacles were experienced 
by Marchev et al. (2011) during the hairy root initiation from Salvia tomentosa Mill. This 
challenge was overcome by use of a novel approach for A. rhizogenes-mediated genetic 
transformation. This approach includes addition of a second phase (Amberlite XAD-4 resin) in 
temporary immersion cultivation systems (RITA®). The presence of the resin had a key role, 
since it could capture the secreted phenolic substances from the leaf explants in response to the 
A. rhizogenes infection. As a result 111 individual hairy root lines were isolated, while in the 
control experiment (without Amberlite XAD-4) all the explants died before hairy roots were 
induced (Marchev et al. 2011). Currently there are several reports for hairy roots obtained from 
Rhodiola species, including R. kirilowii, R. crenulata and R. sachalinensis. The secondary 
metabolite production again faces the same problems as with callus and suspension cultures. 
Salidroside and CAGs were not produced form hairy roots of R. kirilowii without addition of the 
respective precursor tyrosol or CA (Grech-Baran et al. 2013; Grech-Baran et al. 2014). 
Nevertheless, the hairy roots either do not produce the whole spectrum of secondary metabolites 
or produce them in lower amounts compared to the intact plant (Grech-Baran et al. 2014). 
Precursor feeding (tyrosol, tyrosine and phenylalanine) and elicitor treatment (abiotic and biotic) 
increased significantly the expression of key enzymes involved in the salidroside biosynthetic 
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pathway, thus enhancing approximately 2- to 3.5-times the salidroside concentration in 
comparison with wild type non-transformed roots of R. sachalinensis and R. crenulata (Zhou et 
al. 2007; Lan et al. 2013). 
In conclusions, the choice of in vitro cultures depends on the organ in which the 
accumulation of the desired metabolite occurs in the intact plant. The establishment of hairy root 
cultures and laboratory as well as large-scale cultivation of R. rosea in vitro cultures can be taken 
in consideration. The investigations on calli and suspension cultures of R. rosea are still at their 
initial stages. There are still many open questions about the effective application of strategies for 
enhancing the biosynthesis of salidroside and CAGs with regard to optimization of the nutrient 
medium, precursor feeding and genetic engineering. These strategies can be applied single or in 
combination, in order to establish the optimal conditions for sustainable secondary metabolite 
production. 
Conclusions and future perspectives 
R. rosea is a plant species extensively applied as an adaptogenic, antifatigue, antidepressant, 
antioxidant, anti-inflammatory, antinociceptive, and anticancer agent, and modulator of immune 
functions. Application of a safe and effective alternative therapy utilizing natural products could 
be of public health relevance for many individuals unable, or unwilling, to use conventional 
therapies. Numerous clinical trials provide important information for the applicability, safety and 
clinical relevance of R. rosea. Research on molecular mechanisms is essential for understanding 
the signalling and molecular network affected by adaptogens at the cellular level in order to  
rationalize their beneficial effect on emotional behaviour, psychological, neurological and 
metabolite disorders, as well as, mental and physical performance under stress. 
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Regarding the protected status of R. rosea, in vitro cultures of this species are relevant and 
sustainable alternative for production of the pharmaceutically important salidroside and CAGs. 
Current optimization procedures of the growth medium components and the process of cell 
cultivation show promise to increase the biosynthesis of these secondary metabolites. 
Nevertheless, exploring the mechanisms that regulate the biosynthesis of these metabolites is key 
factor in understanding and controlling their biosynthetic pathways in the plant as well as in 
cultures. These approaches, along with the emerging “omics” platforms (metabolomics in 
particular), could be successfully implemented in the manufacturing and chemical profiling of R. 
rosea preparations based on in vitro cultures. 
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Enzymes abbreviation: PAL: Phenylalanine ammonia-lyase (EC:4.3.1.5); TAL: Tyrosine ammonia-lyase 
(EC:4.3.1.23); PTAL: Phenylalanine/tyrosine ammonia-lyase (EC:4.3.1.25); TyrDC: Tyrosine decarboxylase 
(EC:4.1.1.25); HPA: Histidinol-phosphate transaminase (EC:2.6.1.9); AAT: Aromatic-amino-acid transaminase 
(EC: 2.6.1.57); HPPD: 4-hydroxyphenylpyruvate decarboxylase (EC:4.1.1.80); CAO: Primary-amine oxidase  
(EC:1.4.3.21); AAD: Aryl-alcohol dehydrogenase (EC:1.1.1.90); 4CL: 4-coumarate coenzyme A:ligase 
(EC:6.2.1.12); C4H: Trans-cinnamate 4- monooxygenase (EC:1.14.13.11); CCR: Cinnamoyl-CoA reductase 
(EC:1.2.1.44); CAD: Cinnamyl-alcohol dehydrogenase (EC:1.1.1.195); PCD: P-Coumaric acid decarboxylase 
(EC: 4.1.1.-.). 
Figure 2. 
UDP-D-glucose
UDP H+
Trans-cinnamic acid
C4H
Para-Coumaric acid
A
G
B C D
E F
Pentose Phosphate Pathway
Photosynthesis
D-Erythrose 4-phosphate
Phosphoenolpyruvate Glycolysis
Shikimate
Chorismate
Prephenate
Arogenate
(Pretyrosine)
1.3.1.78
1.3.1.43 4.2.1.51
4.2.1.91
Tyrosine
TyrDC
CAO HPPD
AAD
PAL
4CL
CCR
CAD
+ Glucose
Salidroside
HPA
AAT
TAL
PTAL
CCR
4CL
CAD
+ Arabinose
+ Arabinofuranose
UDP-Glc. 
transferase
?
Tyramine 4-Hydroxyphenylpyruvate
4-Hydroxyphenylacetaldehyde
Tyrosol
(4-Hydroxyphenyethanol)
Para-coumaroyl-CoA
Para-coumaraldehyde
Para-coumaryl alcohol
Phenylalanine
Cinnamoyl-CoA
Cinnamaldehyde
Cinnamyl alcohol
Rosin
Rosarin
Rosavin
PCD
37 
 
Table 1. Phytochemical classes of Rhodiola rosea L. 
Chemical group  Reference 
Phenylpropanoid 
glycosides 
Rosarin, Rosavin, Rosin,  
Zapesochnaya and Kurkin 1986, 
Brown et al. 2002, Tolonen et al. 
2003 
Monoterpenes/Glycosides 
Rosiridol, Rosiridin, Sachalinol 
A, Rhodioloside A&B 
Kurkin et al. 1985, Avula et al. 
2009, Ma et al. 2006 
Phenylmethanoids Benzyl-O-β- D-glucopyranoside   
Avula et al. 2009, Mudge et al. 
2013 
Phenylethanoids 
Salidroside, Tyrosol, 
Mongrhoside, Viridoside,  
Troshchenko and Kutikova 1967, 
Avula et al. 2009 
Flavonoids 
Rhodionin, Rhodiolinin, Tricin, 
Kaempferol, Herbacetin, 
Rhodiologidin, Rhodiolin, 
Rhodalidin, Quercetin-3’/4’-
rhamnose 
Zapesochnaya et al. 1983, 
Kurkin et al. 1984, Brown et al. 
2002, Petsalo et al. 2006, Avula 
et al. 2009, Jeong et al. 2009 
Triterpenes Daucosterol, β-Sitosterol 
Kurkin et al. 1985, Dubichev et 
al. 1991 
Phenolic acids 
Caffeic acid, Cholorgenic acid, 
Gallic acid esters 
Kurkin et al. 1991, Brown et al. 
2002 
Cyanogenic glycosides Lotaustralin, Rhodiocyanoside A 
Akgul et al. 2004, van Diermen 
et al. 2009 
Oligomeric/polymeric 
proanthocyanidins 
Prodelphinidin gallates/esters Yousef et al. 2006 
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Table 2. Comparison of the secondary metabolites content in R. rosea in vitro cultures and plants 
Substances,  Natural 
source 
% of DW 
Field 
cultivated 
% of DW 
Callus 
cultures 
% of DW 
Suspension 
cultures 
% of DW 
Reference 
Salidroside 0.36-0.44; 
0.13; 1 
0.61-0.64; 
0.19-0.87 
0.06-0.11 0.07 Furmanowa et al. 1999; Tasheva and Kosturkova 2010; 
Krajewska-Patan et al. 2007b; Galambosi et al. 2015 
Tyrosol 0.006 0.02-0.05 0.03-0.09 0.14 Krajewska-Patan et al. 2007b; Galambosi et al. 2015 
Rosin 0.1; 0.57; 
0.03 
0.14-1.6 0.85-1.1 0.72; 0.78 Kurkin et al. 1988; György et al. 2004; György et al. 
2005; Krajewska-Patan et al. 2007a; Galambosi et al. 
2015 
Rosavin 0.46; 3 0.51-2.67 0.049-0.09; 
0.03-1.01 
0.1; 0.06 Furmanowa et al. 1999; György et al. 2004; Krajewska-
Patan et al. 2007a 
Rosarin 0.08; 0.067-0.132 0.003-
0.0049 
0.001 Krajewska-Patan et al. 2007a; Galambosi et al. 2015 
Gallic acid 0.08 n.d. 0.004; 0.001 Krajewska-Patan et al. 2007a 
Chlorogenic 
acid 
0.02 n.d 0.02-0.05 0.02 Krajewska-Patan et al. 2007a 
n.d – no data available 
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Legend of the figures: 
Figure 1. Some phenylpropanoids, phenylethanoids and gallic acid derivatives found in 
Rhodiola rosea 
Figure. 2. Proposed biosynthetic pathway of salidroside and cinnamyl alcohol glycosides in 
Rhodiola spp. (Based on Ling-ling et al. 2007; Zhang et al. 2011 and Mirmazloum and 
György 2012). 
 
